Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Montalescot, G.
Right arrow Articles by Collet, J.P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Montalescot, G.
Right arrow Articles by Collet, J.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction

G. Montalescot1, R. Choussat and J.P. Collet

Centre Hôpital Universitaire, Pitié-Salpétriére, Paris, France

1 Correspondence: Professor Gilles Montalescot, MD, PhD, Department of Cardiology, Universitaire Pitié-Salpétrière, 47 Boulevard del l'Hôpital, Paris, France 75651.

Abstract

The past 15 years have seen great progress in the treatment of acute myocardial infarction (MI), with the development of thrombolytic agents and catheter-based reperfusion strategies such as percutaneous transluminal coronary angioplasty (PTCA). Because both thrombolytics and PTCA have limitations in achieving large-vessel patency, stenting has been adopted as the treatment modality of choice for planned elective revascularization. In addition, an increasing number of studies have indicated that the class of antiplatelet drugs known as glycoprotein (GP) IIb/IIIa receptor inhibitors can reduce ischaemic events following both elective and acute percutaneous coronary interventions. The results have been unequivocally positive regarding the benefits of these agents in PTCA procedures, but less information is available on their use with primary stenting in acute MI. This article reviews the rationale and emerging evidence supporting the use of GP IIb/IIIa receptor inhibitors in conjunction with primary stenting for acute MI.

Key Words: GP IIb/IIIa receptor inhibitor • primary stenting • acute myocardial infarction • percutaneous transluminal coronary angioplasty • fibrinolysis

References

  1. The TIMI Study Group. The Thrombolysis in Myocardial Infarction trial: phase I findings. N Engl J Med. 1985;312:932–936[Medline]
  2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;i:397–402
  3. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615–1622[Abstract/Free Full Text]
  4. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. J Am Med Assoc. 1997;278:2093–2098[Abstract/Free Full Text]
  5. Wharton TP, McNamara NS. Primary angioplasty should become the standard-of-care at qualified hospitals without on-site cardiac surgery. J Interv Cardiol. 2000;13:145–151
  6. Zahn R, Schiele R, Seidl K, et al. Primary angioplasty in acute myocardial infarction: differences between referred patients and those treated in hospitals with on-site facilities? J Invasive Cardiol. 1999;11:213–219[Web of Science][Medline]
  7. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993;328:673–679[Abstract/Free Full Text]
  8. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680–684[Abstract/Free Full Text]
  9. Suryapranta H, van't Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. 1998;97:2502–2505[Abstract/Free Full Text]
  10. Maillard L, Hamon M, Khalife K, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. J Am Coll Cardiol. 2000;35:1729–1736[Abstract/Free Full Text]
  11. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
  12. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
  13. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037–2044[CrossRef][Web of Science][Medline]
  14. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycorprotein IIb/IIIa receptors. N Engl J Med. 1999;341:319–327[Abstract/Free Full Text]
  15. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
  16. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators. Circulation. 1998;98:734–741[Abstract/Free Full Text]
  17. The EPISTENT Investigator. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92[Web of Science][Medline]
  18. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1996;77:1045–1051[CrossRef][Web of Science][Medline]
  19. Topol E, Mark D, Lincoff M, et al. Outcomes at one year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet. 1999;354:2019–2024[CrossRef][Web of Science][Medline]
  20. Tcheng J. ESPRIT data, presented at the 73rd Scientific Sessions of the American Heart Association. November 12–15, 2000. New Orleans, LA, U.S.A.
  21. Rodriguez A, Bernardi V, Fernandez M, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. Am J Cardiol. 1998;81:1286–1291[CrossRef][Web of Science][Medline]
  22. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998;31:967–972[Abstract/Free Full Text]
  23. Schömig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. 1997;29:28–34[Abstract]
  24. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998;97:211–218[Free Full Text]
  25. Schömig A. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 2000;343:385–391[Abstract/Free Full Text]
  26. Stone GW. CADILLAC trial results, presented at Transcatheter Cardiovascular Therapeutics 2000. October 11–17, 2000. Washington, DC, U.S.A.
  27. Montalescot G, Barragan P, Wittenberg O, et al. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: the ADMIRAL study, 30 day final results (Abstr.). Circulation. 1999;100(Suppl I):I–87
  28. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glyco-protein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915–921[Abstract/Free Full Text]
  29. Neumann F-J, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695–2701[Abstract/Free Full Text]
  30. Smyth DW, Richards M, Hart C, Elliott JM. Abciximab decreases ‘slow flow’ during direct angioplasty for acute anterior myocardial infarction: a randomized study. Presented at the 48th Annual Scientific Session of the American College of Cardiology. March 7–10, 1999. New Orleans, LA, U.S.A.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Montalescot, G.
Right arrow Articles by Collet, J.P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Montalescot, G.
Right arrow Articles by Collet, J.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?